Coagulation factors determine tumor transduction in vivo

Human Gene Therapy

Volumn 19, Issue 12, 2008, Pages 1415-1419

  Gimenez Alejandre, Marta ^a   Cascallo, Manel ^a   Bayo Puxan, Neus ^a   Alemany, Ramon ^a,b  

^a BELLVITGE BIOMEDICAL RESEARCH INSTITUTE IDIBELL   (Spain)

^b CATALAN INSTITUTE OF ONCOLOGY   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; ARGINYLGLYCYLASPARTIC ACID; BLOOD CLOTTING FACTOR 10; BLOOD CLOTTING FACTOR 9; COXSACKIE VIRUS AND ADENOVIRUS RECEPTOR; GREEN FLUORESCENT PROTEIN; VITAMIN K GROUP;

ADENOVIRUS 5; ANIMAL EXPERIMENT; ARTICLE; GENE TARGETING; GENETIC TRANSDUCTION; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; TUMOR CELL LINE; VIRAL GENE DELIVERY SYSTEM; VIRUS INFECTIVITY;

ADENOVIRIDAE; BLOOD COAGULATION; ENTEROVIRUS B, HUMAN; GENE THERAPY; GENETIC VECTORS; HUMANS; NEOPLASMS; TRANSDUCTION, GENETIC; VITAMIN K;

ADENOVIRIDAE; HUMAN ADENOVIRUS TYPE 5; HUMAN ENTEROVIRUS B;

EID: 57749169962     PISSN: 10430342     EISSN: None     Source Type: Journal    
DOI: 10.1089/hum.2008.053     Document Type: Article

References (19)

1. Alemany, R., and Curiel, D.T. (2001). CAR-binding ablation does not change biodistribution and toxicity of adenoviral vectors. Gene Ther. 8, 1347-1353.
2. Bayo-Puxan, N., Cascallo, M., Gros, A., Huch, M., Fillat, C., and Alemany, R. (2006). Role of the putative heparan sulfate glycosaminoglycan- binding site of the adenovirus type 5 fiber shaft on liver detargeting and knob-mediated retargeting. J. Gen. Virol. 87, 2487-2495.
3. Bergelson, J.M., Cunningham, J.A., Droguett, G., Kurt-Jones, E.A., Krithivas, A., Hong, J.S., Horwitz, M.S., Crowell, R.L., and Finberg, R.W. (1997). Isolation of a common receptor for coxsackie B viruses and adenoviruses 2 and 5. Science 275, 1320-1323.
4. Bernt, K.M., Ni, S., Gaggar, A., Li, Z.Y., Shayakhmetov, D.M., and Lieber, A. (2003). The effect of sequestration by nontarget tissues on anti-tumor efficacy of systemically applied, conditionally replicating adenovirus vectors. Mol. Ther. 8, 746-755.
5. Dmitriev, I., Krasnykh, V., Miller, C.R., Wang, M., Kashentseva, E., Mikheeva, G., Belousova, N., and Curiel, D.T. (1998). An adenovirus vector with genetically modified fibers demonstrates expanded tropism via utilization of a coxsackievirus and adenovirus receptor-independent cell entry mechanism. J. Virol. 72, 9706-9713.
6. Hamid, O., Varterasian, M.L., Wadler, S., Hecht, J.R., Benson, A., III, Galanis, E., Uprichard, M., Omer, C., Bycott, P., Hackman, R.C., and Shields, A.F. (2003). Phase II trial of intravenous CI-1042 in patients with metastatic colorectal cancer. J. Clin. Oncol. 21, 1498-1504.
7. Hedley, S.J., Auf Der Maur, A., Hohn, S., Escher, D., Barberis, A., Glasgow, J.N., Douglas, J.T., Korokhov, N., and Curiel, D.T. (2006). An adenovirus vector with a chimeric fiber incorporating stabilized single chain antibody achieves targeted gene delivery. Gene Ther. 13, 88-94.
8. Kalyuzhniy, O., Di Paolo, N.C., Silvestry, M., Hofherr, S.E., Barry, M.A., Stewart, P.L., and Shayakhmetov, D.M. (2008). Adenovirus serotype 5 hexon is critical for virus infection of hepatocytes in vivo. Proc. Natl. Acad. Sci. U.S.A. 105, 5483-5488.
9. Leopold, P.L., and Crystal, R.G. (2007). Intracellular trafficking of adenovirus: Many means to many ends. Adv. Drug Deliv. Rev. 59, 810-821.
10. Lyons, M., Onion, D., Green, N.K., Aslan, K., Rajaratnam, R., Bazan-Peregrino, M., Phipps, S., Hale, S., Mautner, V., Seymour, L.W., and Fisher, K.D. (2006). Adenovirus type 5 interactions with human blood cells may compromise systemic delivery. Mol. Ther. 14, 118-128.
11. Nicol, C.G., Graham, D., Miller, W.H., White, S.J., Smith, T.A., Nicklin, S.A., Stevenson, S.C., and Baker, A.H. (2004). Effect of adenovirus serotype 5 fiber and penton modifications on in vivo tropism in rats. Mol. Ther. 10, 344-354.
12. Parker, A.L., Waddington, S.N., Nicol, C.G., Shayakhmetov, D.M., Buckley, S.M., Denby, L., Kemball-Cook, G., Ni, S., Lieber, A., McVey, J.H., Nicklin, S.A., and Baker, A.H. (2006). Multiple vitamin K-dependent coagulation zymogens promote adenovirus-mediated gene delivery to hepatocytes. Blood 108, 2554-2561.
13. Parker, A.L., McVey, J.H., Doctor, J.H., Lopez-Franco, O., Waddington, S.N., Havenga, M.J., Nicklin, S.A., and Baker, A.H. (2007). Influence of coagulation factor zymogens on the infectivity of adenoviruses pseudotyped with fibers from subgroup D. J. Virol. 81, 3627-3631.
14. Shayakhmetov, D.M., Li, Z.Y., Ni, S., and Lieber, A. (2004). Analysis of adenovirus sequestration in the liver, transduction of hepatic cells, and innate toxicity after injection of fiber-modified vectors. J. Virol. 78, 5368-5381.
15. Shayakhmetov, D.M., Gaggar, A., Ni, S., Li, Z.Y., and Lieber, A. (2005). Adenovirus binding to blood factors results in liver cell infection and hepatotoxicity. J. Virol. 79, 7478-7491.
16. Steiner, I., Aebi, C., Ridolfi Luthy, A., Wagner, B., and Leibundgut, K. (2008). Fatal adenovirus hepatitis during maintenance therapy for childhood acute lymphoblastic leukemia. Pediatr. Blood Cancer 50, 647-649.
17. Stone, D., Liu, Y., Shayakhmetov, D., Li, Z.Y., Ni, S., and Lieber, A. (2007). Adenovirus-platelet interaction in blood causes virus sequestration to the reticuloendothelial system of the liver. J. Virol. 81, 4866-4871.
18. Waddington, S.N., Parker, A.L., Havenga, M., Nicklin, S.A., Buckley, S.M., McVey, J.H., and Baker, A.H. (2007). Targeting of adenovirus serotype 5 (Ad5) and 5/47 pseudotyped vectors in vivo: Fundamental involvement of coagulation factors and redundancy of CAR binding by Ad5. J. Virol. 81, 9568-9571.
19. Waddington S.N., McVey, J.H., Bhella, D., Parker, A.L., Barker, K., Atoda, H., Pink, R., Buckley, S.M., Greig, J.A., Denby, L., Custers, J., Morita, T., Francischetti, I.M., Monteiro, R.Q., Barouch, D.H., Van Rooijen, N., Napoli, C., Havenga, M.J., Nicklin, S.A., and Baker, A.H. (2008). Adenovirus serotype 5 hexon mediates liver gene transfer. Cell 132, 397-409.